Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We have evaluated an oral vaccine based on an Salmonella enteric serovar typhi (S. typhi) Ty2 derivative TSB7 harboring deletion mutations in ssaV (SPI-2) and aroC together with a chromosomally integrated copy of eltB encoding the B subunit of enterotoxigenic Escherichia coli heat labile toxin (LT-B) in volunteers. Two oral doses of 10(8) or 10(9)CFU were administered to two groups of volunteers and both doses were well tolerated, with no vaccinemia, and only transient stool shedding. Immune responses to LT-B and S. typhi lipopolysaccharide were demonstrated in 67 and 97% of subjects, respectively, without evidence of anti-carrier immunity preventing boosting of LT-B responses in many cases. Further development of this salmonella-based (spi-VEC) system for oral delivery of heterologous antigens appears warranted.

Original publication

DOI

10.1016/j.vaccine.2007.03.007

Type

Journal article

Journal

Vaccine

Publication Date

22/05/2007

Volume

25

Pages

4175 - 4182

Keywords

Administration, Oral, Adolescent, Adult, Antibodies, Bacterial, Antitoxins, Bacterial Toxins, Bacterial Vaccines, Blood, Enterotoxins, Enzyme-Linked Immunosorbent Assay, Escherichia coli, Escherichia coli Proteins, Feces, Humans, Immunoglobulin G, Lymphocytes, Middle Aged, Protein Subunits, Salmonella typhi, Vaccines, Attenuated